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ECOG PS of 0 or 1, no prior systemic therapy. In both Phases, G was 
followed immediately by P on Day 1 every 14 days. Cycles were 
repeated for 12 treatments or until disease progression. All pts received 
folic acid, Vitamin B12 and steroid prophylaxis.
Results: Phase I dose-escalation resulted in a recommended Phase 2 
dose of G 1500 mg/m2 followed by P 500mg/m2. DLTs at this level 
were G3 diarrhea, hypotension, and atrial ﬁbrillation. 53 pts (29 male, 
24 female) were enrolled in Phase 2: median age = 64 (range: 35, 80), 
ECOG performance status 0:1 = 38%:60%, Stage IIIB:IV = 19%:81%. 
312 cycles of treatment were administered and 14 patients had dose 
reductions (26.4%); median number of doses was 5 for both G and P, 
and median dose intensity was 98.05% for both G and P. Conﬁrmed 
responses were 0 CRs, 11 PRs, (20.8%), 23 SDs (43.4%), and 14 PDs 
(26.4%), with a median duration of response of 10.3 mos (95%CI, 3.2, 
20.0). Patient-based G3/4 hematologic events included febrile neu-
tropenia (9.4%), neutropenia (28.3%), and thrombocytopenia (5.7%). 
Grade 3/4 nonhematologic events included fatigue (22.6%), dyspnea 
(7.5%), dehydration (7.5%), diarrhea (5.7%), constipation (3.8%), nau-
sea (3.8%), ALT elevation (3.8%), and pneumonia (1.9%). Median TTP 
was 4.6 mos (95%CI, 2.8, 6.2; 30.2% censored) and median OS was 
10.1 mos (95%CI, 6.0, 14.1; 41.0% 1-yr survival; 20.8% censored).
Conclusion: Biweekly G and P appear to be well tolerated in advanced 
NSCLC. A median OS of 10.1 mos and clinical beneﬁt rate (ORR + 
SD) of 64.2% indicates activity in patients with advanced NSCLC. The 
dose intensity for biweekly G and P is higher than a previously reported 
6-cycle, 21-day regimen with median dose intensity of 83.2% for P and 
82.2% for G (West, et al. Proc ASCO 2005; 7117).
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Background: We conducted retrospective study to evaluate efﬁcacy 
and tolerability to single-agent TS-1 which is a newly developed oral 
ﬂuoropyrimidine anti-tumor agent chemotherapy in advanced non-
small cell lung cancer patients who received two or three standard or 
approval chemotherapy regimens including platinum and docetaxel 
and/or EGFR-TKIs in clinical practice. 
Methods: Sixty three patients treated single agent TS-1 chemotherapy 
for advanced NSCLC between January 2005 and November 2006 at 
the Shizuoka Cancer Center and 35 patients were fulﬁlled criteria. The 
treatment schedule comprised an oral administration of TS-1 at 120mg 
/ day, one cycle of TS-1 consisted of consecutive administration for 28 
days followed by a 14 days rest.
Results: All 35 patients were evaluable for survival, response and 
toxicity. Patients proﬁles were; M/F 27/8, median age 63 (range:42-77), 
PS 0/1/2 18/14/3, adeno/ non-adeno 24/11 number of prior chemother-
apy 2/3/>4 4/14/17. All adeno patients had been administered EGFR-
TKIs. Median number of delivered cycle is two cycles (range 1-9). Of 
these 35 patients, 2 (5.7%) experienced partial response, 12 (34.2%) 
stable disease. The median survival time and time to progression 
after initiation of oral TS-1 administration was 208 days and 43 days, 
respectively. 1-year survival rate was 37.8%. Toxicities were mild as 
follows: G 3/4 neutropenia 3%, G 3/4 anemia 6%, G 3/4 diarrhea 6%, 
G 3/4 nausea/vomiting, anorexia, fatigue, stomatitis, 3%, respectively. 
As unexpected toxicity, G3 pneumonitis occurred in one patient. 
Conclusions: Single-agent TS-1 chemotherapy has modest activity in 
patients with NSCLC after failed platinum and docetaxel and/or EGFR-
TKI chemotherapy. 
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Platinum-based chemotherapy has been proved effective in patients 
with advanced non-small cell lung cancer (NSCLC). Among these 
regimens, the combination of carboplatin and gemcitabine is one of the 
most active against NSCLC. However, the optimal administration regi-
men has not yet been determined. This study aims to evaluate response 
rates with gemcitabine as a 120-minutes’ perfusion versus a 30-min-
utes’ perfusion, both combined with carboplatin.
Randomized, prospective, multicenter, phase II study. Patients with 
stage IIIB or IV, ECOG performance status 0-1, who had not had prior 
chemotherapy, were assigned to receive gemcitabine 1200 mg/m2 iv, 
10mg/m2/min (arm A) or 30 minutes perfusion (arm B) (days 1 and 8) 
plus carboplatin AUC 5 iv in continuous perfusion (day 1). The cycles’ 
duration was 21 days and 6 cycles were foreseen.
Ninety seven patients were enrolled (48 in arm A and 49 in arm B), 
76.0% men, mean age 63.8±9.1 years (46-87 range), 45.4% smokers.
The most frequent NSCLC histological subtypes were adenocarci-
noma (52.6%) and epidermoid carcinoma (29.7%). Diagnostic was 
histological in 63.2% of the patients, cytological in 32.6% and both 
in 4.2%. Nineteen patients had stage IIIB (19.6%) and 78 stage IV 
(80.4%); ECOG performance status 0 in 7.4% of the patients and 1 in 
92.6%. Pre-treatment cancer metastases were found in lungs (56.4%), 
liver (25.6%), bone (25.6%), suprarenal (17.9%) and lymphatic nodes 
(5.1%). A total of 413 chemotherapy cycles were administered with a 
median of 4 cycles (range 2-6).
After 6 cycles, 24 patients died (11 in arm A and 13 in arm B); 10 
deaths were not considered as disease progression. 
Response rate was evaluated in 87 patients (39 in arm A and 48 in arm 
B). No patient achieved complete response. Partial response was 17.9% 
vs. 18.8%; stable disease rate was 15.4% and 14.6% and progression 
disease rate was 33.3% and 45.8%, arm A and B, respectively. Thirteen 
patients from arm A and 10 from B survived, however their response to 
treatment was not yet evaluated. There were no signiﬁcant differences 
between groups.
Thirteen percent of the patients discontinued treatment due to toxicity. 
Twelve adverse events were considered serious.
According to the WHO toxicity scale, 26.8% of the patients had grade 
3-4 neutropenia and 8.2% had grade 3-4 thrombocytopenia. The other 
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toxicities were fatigue; nausea; asthenia, vomiting and arthralgia/ 
myalgia.
More than forty percent of the patients received 2nd line therapy and, 
from those, 23% were responsive to the treatment.
Maintenance therapy with gemcitabine in perfusion for 120 minutes 
versus for 30 minutes both combined with carboplatin, showed similar 
response rates and safety proﬁles.
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Background: NSCLC is a common malignancy worldwide-including 
developing countries like India. The standard treatment of advanced 
stage NSCLC is platinum doublet chemotherapy, one of the most ac-
tive being Gemcitabine- platinum combination. Gemcitabine requires 
conversion by deoxycytidine kinase into its active metabolite. This rate 
limiting step can be circumvented by prolonging infusion duration. 
Methods: In the present study we treated 75 elderly patients (age 60 or 
more) having advanced stage NSCLC with low dose prolonged infu-
sion Gemcitabine (350mg/m2 over 4 hours, Day 1 and Day 8) and stan-
dard dose Carboplatin (AUC-5, Day 1 only) repeated every 3 weeks for 
maximum 6 cycles. 
Results: There were 60 (80%) males and 15 females. Of them 43 were 
between the age of 60 and 65 yrs, 18 between the age of 65 and 70 
whereas 14 patients were above the age of 70 yrs. PS was 1 in 54 and 2 
in 24 cases. Stage wise distribution was 40 (53.3 %) with Stage IV and 
35 (46.7 %) with Stage IIIB. Histopathology was adenocarcinoma in 
46, squamous cell in 14 and not speciﬁed in the remaining 15 patients. 
Of these 75, 30 had signiﬁcant co-morbidities. Chemotherapy was 
administered by medical oncologists in 43 patients and others (other 
oncologists/ non oncologists) in the remaining 32 cases. All 6 cycles 
were completed in 46 (61.33 %) of patients - 33 completed all 6 cycles 
without any dose reduction, 13 completed 6 cycles with dose reduc-
tion and 29 could be goven less than 6 cycles of CT. Partial response 
was seen in 19 ( 25.3 %), stable disease in 36 (48 %) and progressive 
disease in 20 (26.7 %). There was no treatment related mortality. The 
median overall survival was 11 months (range 1 - 34 months). There 
were signiﬁcant differences among patients treated by medical oncolo-
gists (group 1) and by others (group 2). The overall RR was 37.2 % 
(16/43) in Group 1 and 9.4 % (3/32) in Group 2. The median survival 
was 13 months in Group 1 and 6 months in Group 2 (p value = 0.004), 
the overall RR was and the medial OS was 6 months. These differences 
were statistically signiﬁcant. 
Conclusions: We conclude that low dose prolonged infusion gem-
citabine and standard carboplatin combination is an effective treatment 
for patients above the age of 60 years with advanced stage NSCLC. 
Dose intensity impacts on RR as well as overall survival and is best 
optimized when chemotherapy is administered by medical oncologists.
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Background: Docetaxel and gemcitabine combination chemotherapy 
has been reported to be active against non-small cell lung cancer 
(NSCLC) and myelosuppression was the most common dose-limit-
ing toxicity. This prospective phase II study was designed to test the 
hypothesis that better tolerance and increased dose intensity might be 
achieved if patients are treated with weekly administration schedule.
Methods: Consenting patients with stage IIIB/IV or recurrent NSCLC 
received ﬁrst-line chemotherapy with docetaxel 35 mg/m2 and gem-
citabine 600 mg/m2 on days 1, 8 and 15. Treatment was repeated every 
4 weeks, for up to 4 cycles.
Results: Of the 35 patients who started treatment, only 6 patients 
(17%) completed planned 4 cycles of therapy. Other than the comple-
tion of all planned treatment cycles, the main reasons for treatment 
discontinuation were toxicity (43%) and progressive disease (40%). 
The most frequently encountered toxic effects were anemia (52% of pa-
tients), nausea and vomiting (60%), fatigue (71%) and anorexia (57%). 
One patient died of bilateral pneumonitis shortly after the adminis-
tration of ﬁrst cycle. Disease control (objective response and stable 
disease) in the ITT population was achieved in 49% of patients and the 
overall response rate was 29% (95% CI, 14 to 44%). With a median 
follow-up duration of 9.2 months, the median progression-free survival 
was 2.8 (95% CI, 0.7 to 4.8) months and the 1-year survival was 53%.
Conclusion: Weekly schedule of docetaxel and gemcitabine has mod-
est activity in advanced NSCLC. This regimen offered no potential 
advantages over standard treatment approaches.
